Phase 1 will investigate maximum tolerated dose of OXi4503 as a single agent and in
combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or
Phase 2 will investigate overall response rate of OXi4503 in combination with
intermediate-dose cytarabine in 1) subjects with MDS after failure of 1 prior
hypomethylating agent (Arm A) and 2) subjects with relapsed and refractory AML after
treatment failure of up to 1 prior chemotherapy regimen (Arm B).